Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
The Oncologist|December 8, 2017
The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of BiosimilarsJennifer R Brown, Florence Cymbalista, Jeff Sharman, et al.
Future Oncology (London, England)|January 21, 2021
Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet needSiwen Hu-Lieskovan, Gabriel G Malouf, Ira Jacobs, et al.
European Journal of Applied Physiology|April 2, 2013
Role of exercise duration on metabolic adaptations in working muscle to short-term moderate-to-heavy aerobic-based cycle trainingHoward J Green, Margaret Burnett, Sherry Carter, et al.
Journal for Immunotherapy of Cancer|November 29, 2019
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?Andrew B Nixon, Kurt A Schalper, Ira Jacobs, et al.
British Journal of Cancer|July 14, 2018
Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancerPhilip E Lammers, Magdolna Dank, Riccardo Masetti, et al.
Future Oncology (London, England)|April 26, 2018
Bevacizumab biosimilars: scientific justification for extrapolation of indicationsBarbara Melosky, David A Reardon, Andrew B Nixon, et al.
Frontiers in Oncology|January 24, 2022
Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug DevelopmentTimothy A Yap, Ira Jacobs, Elodie Baumfeld Andre, et al.
Clinical Pharmacology and Therapeutics|February 17, 2019
Bispecific Antibodies in the Treatment of Hematologic MalignanciesJohannes Duell, Philip E Lammers, Ivana Djuretic, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 4, 2016
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published EvidenceIra Jacobs, Danielle Petersel, Lesley G Shane, et al.
Pageof 8